Scinai Immunotherapeutics Reports Strong First-Half 2025 Results with Revenue Growth and Enhanced Financial Position

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported substantial financial and operational progress for the six months ended June 30, 2025, with revenues increasing to $773,000 compared to $284,000 in the prior-year period. This growth reflects the continued expansion of the company's contract development and manufacturing organization (CDMO) business, which has secured $1.0 million in service orders through August 2025.

The company significantly reduced its research and development expenses to $1.24 million from $2.79 million year-over-year, while marketing, general and administrative expenses increased to $1.26 million from $1.00 million. Net loss narrowed to $4.13 million compared to $4.48 million in the same period last year, demonstrating improved operational efficiency.

Scinai's cash position strengthened considerably, with cash and equivalents totaling $989,000 as of June 30, 2025. The company further enhanced its liquidity by raising an additional $4.2 million in July and August under its Standby Equity Purchase Agreement, providing substantial financial flexibility for ongoing operations and strategic initiatives.

The company advanced its anti-IL-17 NanoAb program, filing new patents through its collaboration with Max Planck Institute. Scinai is actively pursuing up to €27 million in grant funding to support clinical trials and pipeline development, which could accelerate the commercialization of its innovative inflammation and immunology therapeutic products. Additional information about the company's developments is available at https://ibn.fm/SCNI.

Scinai's dual business model combines in-house development of biological therapeutics with boutique CDMO services, positioning the company to capitalize on both proprietary drug development and the growing demand for outsourced biopharmaceutical services. The company's focus on VHH antibody fragments (nanoAbs) targets diseases with significant unmet medical needs, representing a substantial market opportunity in the biopharmaceutical industry.

The financial improvements and strategic advancements position Scinai for continued growth in the competitive biopharmaceutical landscape. The strengthened cash position enables the company to pursue clinical development milestones while maintaining operational stability. The progress in both therapeutic development and CDMO services demonstrates Scinai's ability to execute on its business strategy while creating value for stakeholders in the healthcare innovation ecosystem.